Announcements Trials
Browse Landscape

Phase

Phase 1 1

Status

Active not recruiting 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Sarcoma 1Head & Neck 1Genitourinary 1Gastrointestinal 1Dermatologic 1CNS 1Breast 1

Conditions

Carcinoma, Non-Small-Cell Lung 78Lung Neoplasms 44Carcinoma, Hepatocellular 42Small Cell Lung Carcinoma 28Breast Neoplasms 18Cholangiocarcinoma 17Urinary Bladder Neoplasms 16Biliary Tract Neoplasms 15Liver Neoplasms 13Neoplasms 12Neoplasm Metastasis 12Triple Negative Breast Neoplasms 11Pancreatic Neoplasms 11Ovarian Neoplasms 9Carcinoma 9Squamous Cell Carcinoma of Head and Neck 8Endometrial Neoplasms 7Colorectal Neoplasms 7Stomach Neoplasms 6Carcinoma, Transitional Cell 6Melanoma 5Gallbladder Neoplasms 5Esophageal Neoplasms 5Carcinoma, Renal Cell 5Adenocarcinoma Of Esophagus 5Adenocarcinoma 5Prostatic Neoplasms 4Non-Muscle Invasive Bladder Neoplasms 4Neoplasms by Site 4Mesothelioma 4

Interventions

regorafenib 2ivosidenib 2Proton Therapy 2enasidenib 1durvalumab 1capivasertib 1abemaciclib 1Zoledronic Acid 1Weight-Bearing 1Taxes 1Surveys and Questionnaires 1Standard of Care 1Range of Motion, Articular 1Pharmacogenomic Testing 1Paclitaxel 1Immunoglobulin G 1HhAntag691 1Gemcitabine 1Disulfides 1Cisplatin 1Bevacizumab 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Chondrosarcoma × durvalumab × 1 year × Clear all
NCT04521686 2026-04-22

Study of LY3410738 Administered to Patients With Advanced Solid Tumors With IDH1 or IDH2 Mutations

Eli Lilly and Company

Phase 1 Active not recruiting
200 enrolled
BreastCNSDermatologicGastrointestinalGenitourinaryHead & NeckSarcoma

Breast Neoplasms, Chondrosarcoma, Colonic Neoplasms, Glioblastoma, Glioma, Melanoma, Prostatic Neoplasms, Thyroid Neoplasms, Central Nervous System Neoplasms, Cholangiocarcinoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡